AI-generated analysis. Always verify with the original filing.
Tvardi Therapeutics reported a reduced net loss of $7.3 million for Q4 2025 and announced upcoming clinical milestones for its STAT3 inhibitors TTI-101 and TTI-109, with cash expected to fund operations into Q4 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or
. Financial Statements and Exhibits.** ** ** ** (d) Exhibits ** ** ** | Exhibit No. | | Description | |---|---|---| | 99.1 | | Press release issued on March 31,
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $5.49 | |
| General and Administrative Expenses | $2.10 | |
| Net Loss | $7.28 | |
| Basic Net Loss Per Share | $0.78 | |
| Diluted Net Loss Per Share | $0.78 | |
| Research and Development Expenses | $18.01 | |
| General and Administrative Expenses | $8.74 | |
| Net Loss | $18.21 | |
| Basic Net Loss Per Share | $2.46 | |
| Diluted Net Loss Per Share | $3.26 |